Specific Phobia & Social Anxiety Disorder

Specific phobia and social anxiety disorder (SAD) are among the commonest anxiety disorders, defined by excessive, persistent fear that is out of proportion to actual danger, cued by a circumscribed object/situation (specific phobia) or by social/performance scrutiny (SAD). NEET PG loves the treatment hierarchy — exposure-based therapy as first line, propranolol for discrete performance anxiety, and SSRIs/SNRIs for generalised SAD.

Definition & classification

Both disorders sit within the anxiety disorders chapter of DSM-5-TR and ICD-11. The unifying theme is anticipatory anxiety, phobic avoidance, and recognition (in adults) that the fear is excessive. Crucially, the disorders are differentiated by the focus of the fear rather than the intensity.

• Specific phobia — marked fear/anxiety about a specific object or situation (the phobic stimulus), almost always provoking immediate anxiety, leading to active avoidance.
• Social anxiety disorder (social phobia) — marked fear of one or more social situations involving possible scrutiny by others, with the core fear being humiliation, embarrassment, or negative evaluation.

High-yield: The defining cognition in SAD is fear of negative evaluation/embarrassment. In specific phobia, the fear is about the object/situation itself (or its consequences, e.g. fainting at the sight of blood), not about social judgement.

DSM-5 subtypes of specific phobia

Subtype	Phobic stimulus	Classic exam point
Animal	Spiders, dogs, insects, snakes	Most common; early childhood onset
Natural environment	Heights (acrophobia), storms, water	—
Blood-injection-injury (BII)	Blood, needles, injury, invasive procedures	Biphasic (diphasic) vasovagal response → fainting
Situational	Aeroplanes, lifts, enclosed spaces, driving	Onset bimodal (childhood + mid-20s)
Other	Choking, vomiting (emetophobia), costumed characters, loud sounds	"Catch-all" group

High-yield: The blood-injection-injury type is the odd one out — it produces a vasovagal response (initial sympathetic surge → then a sharp parasympathetic drop in heart rate and BP → fainting/syncope). All other phobias cause sustained tachycardia. This is why applied tension (not relaxation) is the behavioural treatment of choice for BII phobia.

Subtypes / specifiers of social anxiety disorder

• Performance-only specifier (SAD, performance type): fear restricted to public speaking or performing (musicians, athletes, examinees). Does NOT extend to everyday social interaction (eating, conversing).
• Generalised SAD (most situations): fear across most social and interactional settings; more disabling, earlier onset, higher comorbidity, and worse prognosis.

High-yield: The performance-only subtype is the one treated with β-blockers (propranolol) on a PRN basis. Generalised SAD is treated with SSRIs/SNRIs + CBT, not β-blockers.

Etiology & pathophysiology

Multifactorial — gene-environment interplay:

1. Genetic/temperamental — heritability ~30-40%. Behavioural inhibition to the unfamiliar in toddlers is the strongest temperamental predictor of later SAD. BII phobia shows the strongest familial aggregation (often autosomal dominant pattern of vasovagal fainting).
2. Neurobiological — amygdala hyperactivity to threatening/socially evaluative faces is the central finding. Reduced prefrontal (ventromedial PFC) top-down inhibition. Serotonergic and dopaminergic dysregulation implicated (hence SSRI efficacy).
3. Learning theory (Mowrer's two-factor model) — Classical conditioning (acquires the fear) → Operant conditioning (avoidance is negatively reinforced because it relieves anxiety) → the phobia is maintained.
4. Preparedness theory (Seligman) — humans are evolutionarily "prepared" to fear stimuli that threatened ancestors (snakes, heights, spiders), explaining why these phobias predominate over modern dangers (e.g. electric sockets).

High-yield: Avoidance is the engine that maintains every phobia — it prevents extinction of the conditioned fear. Exposure therapy works by preventing avoidance, allowing habituation/extinction.

Clinical features

• Anticipatory anxiety that builds well before encountering the stimulus.
• Immediate fear/panic on exposure — palpitations, sweating, tremor, dyspnoea, nausea, derealisation; may culminate in a situationally bound panic attack.
• Phobic avoidance, or endurance with intense distress.
• Insight — in adults the fear is recognised as excessive (children may lack this; fear may be expressed as crying, tantrums, freezing, or clinging).
• Duration ≥ 6 months (a DSM-5 change that applies to both, regardless of age — reduces over-diagnosis of transient childhood fears).

Specific SAD features: blushing (a hallmark, often the chief complaint in Indian patients), avoidance of eye contact, fear of trembling/voice cracking, dread of writing/eating/urinating in public. Adolescent onset is typical (median ~13 years).

Feature	Specific phobia	Social anxiety disorder
Focus of fear	Object/situation itself	Scrutiny, negative evaluation
Typical onset	Childhood (7-10 yrs)	Adolescence (~13 yrs)
Sex ratio	Female > male (esp. animal/situational)	Roughly equal (slight F>M)
Cardinal sign	Object-cued panic	Blushing, fear of embarrassment
First-line Rx	Exposure / systematic desensitisation	CBT + SSRI/SNRI
Drug of choice	Usually none (therapy alone)	SSRI (escitalopram/paroxetine/sertraline)

Diagnosis & investigation of choice

Diagnosis is clinical, based on DSM-5-TR/ICD-11 criteria. There is no confirmatory lab test — investigations are used to exclude organic mimics (thyrotoxicosis, phaeochromocytoma, arrhythmia, hypoglycaemia, substance/caffeine use).

DSM-5 criteria (shared skeleton)

1. Marked fear/anxiety about a specific object/situation (or social situation with possible scrutiny).
2. The stimulus almost always provokes immediate fear/anxiety.
3. Actively avoided or endured with intense distress.
4. Fear is out of proportion to actual danger/sociocultural context.
5. Persistent, ≥ 6 months.
6. Clinically significant distress/impairment.
7. Not better explained by another disorder.

Rating scales (commonly tested):

• Liebowitz Social Anxiety Scale (LSAS) — the standard SAD severity/treatment-response scale.
• Social Phobia Inventory (SPIN) and Brief Fear of Negative Evaluation (BFNE) scale.

High-yield: Always screen for comorbid major depression and alcohol/substance use in SAD — patients frequently "self-medicate" social fear with alcohol, and SAD usually precedes the alcohol use disorder.

Management / drug of choice

The guiding principle: psychotherapy (exposure-based CBT) is first-line for both; pharmacotherapy is added in generalised SAD or when therapy is inaccessible.

Stepwise approach to specific phobia

Psychoeducation → graded exposure (systematic desensitisation) → flooding/VRET if needed → applied tension for BII type. Drugs play almost no role.

Behavioural techniques (know the differences cold)

Technique	Method	Key point
Systematic desensitisation (Wolpe)	Relaxation training → construct fear hierarchy → graded exposure while relaxed	Based on reciprocal inhibition (counter-conditioning); gradual
Flooding	Direct, prolonged exposure to the most feared stimulus, no hierarchy	In vivo; rapid but distressing
Implosion	Imaginal flooding (in imagination, often exaggerated)	Not in vivo
Applied tension	Repeatedly tense large muscles to raise BP before/during exposure	BII phobia — prevents vasovagal faint
Virtual reality exposure therapy (VRET)	Computer-simulated phobic environment	Excellent for flying, heights, public speaking; non-inferior to in vivo
Modelling (Bandura)	Patient observes someone interact fearlessly with the stimulus	Social/vicarious learning

High-yield: Systematic desensitisation = relaxation + a graded fear hierarchy, working bottom-up; its theoretical basis is reciprocal inhibition (anxiety and relaxation cannot coexist). This three-step sequence is a favourite single-best-answer.

Pharmacotherapy of social anxiety disorder

Indication	Drug of choice	Notes
Generalised SAD (maintenance)	SSRI — escitalopram, paroxetine, sertraline; or SNRI venlafaxine	First-line; FDA-approved: paroxetine, sertraline, venlafaxine ER, fluvoxamine CR
Performance anxiety (discrete, PRN)	Propranolol 10-40 mg, ~30-60 min before event	Blocks peripheral autonomic symptoms (tremor, tachycardia, sweating)
Treatment-resistant	MAOIs (phenelzine) — historically very effective	Limited by tyramine diet/interactions
Short-term bridge	Benzodiazepine (clonazepam)	Avoid if alcohol-use comorbidity; not first-line

High-yield: Propranolol is the classic answer for a violinist/public speaker/examinee with performance anxiety — it abolishes the somatic signs (hand tremor, racing heart) without sedation. It does not treat generalised SAD and is taken as-needed before the event, not daily.

High-yield: For everyday/generalised social anxiety, the long-term drug of choice is an SSRI (commonly escitalopram or paroxetine); response takes 4-6 weeks and treatment continues 6-12 months. CBT has the most durable effect after stopping treatment.

Mnemonic — "PROP before you PERFORM": PROPranolol for PERFORMance-only anxiety; SSRI for the rest.

Complications

• Major depressive disorder — the commonest comorbidity, especially in generalised SAD.
• Alcohol & substance use disorders — self-medication; SAD typically antedates the substance problem.
• Educational/occupational impairment — school refusal, dropping out, under-employment; SAD is a leading cause of not progressing despite ability.
• Other anxiety disorders, panic disorder, body dysmorphic disorder.
• Suicidality — raised, largely mediated by comorbid depression.
• BII phobia specifically → avoidance of necessary medical/dental care, vaccination, blood donation, antenatal care.

Key differentials

Condition	Discriminator from phobia/SAD
Panic disorder + agoraphobia	Panic attacks are unexpected/spontaneous; agoraphobia fear is of not being able to escape/get help, not of scrutiny or a single object
Generalised anxiety disorder	Worry is free-floating across many life domains, not cued by a specific stimulus
Obsessive-compulsive disorder	Avoidance driven by obsessions (e.g. contamination), with compulsions
PTSD	Avoidance follows an identifiable trauma; re-experiencing phenomena present
Autism spectrum / avoidant personality	Pervasive social deficits/traits from early life; in autism, social motivation itself is reduced
Body dysmorphic disorder	Social avoidance is due to perceived physical defect
Normal shyness / stage fright	No significant distress or functional impairment; under 6 months or proportionate

High-yield: The single best discriminator between SAD and panic disorder with agoraphobia is the content of the fear — scrutiny/embarrassment (SAD) versus being trapped/unable to escape or get help (agoraphobia).

Recently asked / exam angle

• Drug for performance/stage anxiety → Propranolol (β-blocker; abolishes somatic symptoms). Repeatedly tested.
• Treatment of choice for blood-injection-injury phobia → Applied tension (NOT relaxation), because the response is vasovagal fainting.
• Systematic desensitisation steps / its basis → relaxation + graded hierarchy; principle = reciprocal inhibition (Wolpe).
• Best treatment for flying/heights phobia → graded exposure / virtual reality exposure therapy (VRET).
• First-line long-term drug for generalised social anxiety disorder → SSRI (escitalopram/paroxetine/sertraline).
• Most durable treatment → CBT/exposure (effect persists after discontinuation, unlike drugs).
• Strongest childhood temperamental predictor of SAD → behavioural inhibition.
• Two-factor (Mowrer) model — classical conditioning acquires, operant (avoidance) maintains the phobia.
• Eponym matches: Wolpe → systematic desensitisation/reciprocal inhibition; Bandura → modelling; Seligman → preparedness; Liebowitz → social anxiety scale.
• Minimum duration for diagnosis in both → ≥ 6 months (DSM-5).

Rapid revision

1. Specific phobia = fear of the object itself; SAD = fear of negative evaluation/scrutiny.
2. Blood-injection-injury phobia → biphasic vasovagal response → syncope; treat with applied tension, not relaxation.
3. All other phobias → sustained sympathetic tachycardia.
4. Propranolol = drug of choice for performance-only social anxiety (PRN, ~30-60 min pre-event).
5. SSRI/SNRI = first-line drug for generalised SAD; CBT/exposure = most durable treatment overall.
6. Systematic desensitisation (Wolpe) = relaxation + graded fear hierarchy; basis = reciprocal inhibition.
7. Flooding = full-intensity in vivo exposure, no hierarchy; implosion = imaginal version.
8. VRET is the modern, evidence-based option for flying, heights, and public-speaking phobias.
9. Behavioural inhibition in toddlers is the strongest temperamental predictor of SAD.
10. Mowrer's two-factor theory: classical conditioning acquires, avoidance (operant) maintains.
11. Minimum duration for diagnosis = ≥ 6 months; insight present in adults, may be absent in children.
12. Screen every SAD patient for depression and alcohol use (SAD usually precedes alcohol misuse).